微小RNA 29a和微小RNA 335在乳腺癌治疗中的临床作用：它们与基质金属蛋白酶2蛋白水平的相关性。
Clinical role of MiRNA 29a and MiRNA 335 on breast cancer management: their relevance to MMP2 protein level.
作者信息
Ali Ahmed Elham, Abd El-Basit Sohir A, Mohamed Mona A, Swellam Menha
机构信息
Zoology Department, Faculty of Science (Girls), Al-Azhar University, Cairo, Egypt.
Biochemistry Division, Chemistry Department, Faculty of Science (Girls), Al-Azhar University, Cairo, Egypt.
出版信息
Arch Physiol Biochem. 2022 Aug;128(4):1058-1065. doi: 10.1080/13813455.2020.1749085. Epub 2020 Apr 8.
BACKGROUND
Circulating miRNAs are novel biomarkers, authors aimed to investigate the expression level of miR-29a and miR-335 and their relevance to CEA, CA15.3, and matrix metalloproteinase-2 (MMP2).
MATERIALS AND METHODS
Breast cancer (BC) patients ( = 44), benign breast lesion patients ( = 25), and healthy individuals ( = 19) were enrolled for detection of miRNA expression levels, MMP2 and biochemical markers using quantitative polymerase chain reaction (PCR) and ELISA, respectively.
RESULTS
Expression of miR-29a and miR-335 were significantly decreased in breast patients as compared to healthy individuals, while biochemical markers were high in BC patients as compared to the other two groups. The diagnostic efficacy for miR-29a, miR-335, and MMP2 were superior to both CEA and CA 15.3 for early detection of BC patients.
CONCLUSIONS
Detection of the miR-29a and miR335 expression levels in serum samples are significant promising biomarkers for BC diagnosis.
背景
循环miRNA是新型生物标志物，作者旨在研究miR-29a和miR-335的表达水平及其与癌胚抗原（CEA）、糖类抗原15.3（CA15.3）和基质金属蛋白酶-2（MMP2）的相关性。
材料与方法
纳入乳腺癌（BC）患者（n = 44）、乳腺良性病变患者（n = 25）和健康个体（n = 19），分别采用定量聚合酶链反应（PCR）和酶联免疫吸附测定（ELISA）检测miRNA表达水平、MMP2及生化标志物。
结果
与健康个体相比，乳腺癌患者中miR-29a和miR-335的表达显著降低，而与其他两组相比，乳腺癌患者的生化标志物水平较高。miR-29a、miR-335和MMP2对乳腺癌患者早期检测的诊断效能优于CEA和CA15.3。
结论
检测血清样本中miR-29a和miR-335的表达水平是乳腺癌诊断中极具前景的生物标志物。
Zotero 插件